Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of <i>CFHR1</i>/<i>CFHR3</i> and the presence of CFH antibodies.

Münch, Johannes; Bachmann, Anette; Grohmann, Maik; Mayer, Christof; Kirschfink, Michael; Lindner, Tom H; Bergmann, Carsten; Halbritter, Jan

Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of CFHR1/CFHR3 and the presence of CFH antibodies.

Münch, Johannes; Bachmann, Anette; Grohmann, Maik; Mayer, Christof; Kirschfink, Michael; Lindner, Tom H; Bergmann, Carsten; Halbritter, Jan.

Afiliação

Münch J; Division of Nephrology, Department of Internal Medicine, University Clinic Leipzig, Germany.
Bachmann A; Division of Nephrology, Department of Internal Medicine, University Clinic Leipzig, Germany.
Grohmann M; Center for Human Genetics, Bioscientia, Ingelheim, Germany.
Mayer C; Division of Nephrology, Department of Internal Medicine, University Clinic Leipzig, Germany.
Kirschfink M; Institute of Immunology, University of Heidelberg, Heidelberg, Germany.
Lindner TH; Division of Nephrology, Department of Internal Medicine, University Clinic Leipzig, Germany.
Bergmann C; Center for Human Genetics, Bioscientia, Ingelheim, Germany.
Halbritter J; Division of Nephrology, Department of Internal Medicine, University Clinic Leipzig, Germany.

Clin Kidney J ; 10(6): 742-746, 2017 Dec.

Article em En | MEDLINE | ID: mdl-29225802

Palavras-chave

atypical haemolytic uraemic syndrome; recurrence; renal transplantation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clin Kidney J Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google